Literature DB >> 33221822

Targeting histone deacetylases for combination therapies in neuroendocrine tumors.

Teresa Gagliano1, Claudio Brancolini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33221822     DOI： 10.1038/s41417-020-00260-x

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  4 in total

Review 1.  Histone Lysine Methylation Modification and Its Role in Vascular Calcification.

Authors:  Ye-Chi Cao; Su-Kang Shan; Bei Guo; Chang-Chun Li; Fu-Xing-Zi Li; Ming-Hui Zheng; Qiu-Shuang Xu; Yi Wang; Li-Min Lei; Ke-Xin Tang; Wen-Lu Ou-Yang; Jia-Yue Duan; Yun-Yun Wu; Muhammad Hasnain Ehsan Ullah; Zhi-Ang Zhou; Feng Xu; Xiao Lin; Feng Wu; Xiao-Bo Liao; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

Review 2.  Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Judy S Crabtree
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Cancer gene therapy 2020: highlights from a challenging year.

Authors:  Georgios Giamas; Teresa Gagliano
Journal:  Cancer Gene Ther       Date:  2021-05-07       Impact factor: 5.854

Review 4.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.